Janssen Biotech and AbbVie company Pharmacyclics are jointly developing and commercializing Imbruvica, which blocks a specific protein called Bruton’s tyrosine kinase. The Imbruvica labeling now includes OS results
The projects will investigate the company’s libraries of consortia microbial compounds for potential drug discovery in pediatric cancer (neuroblastoma), liver cancer (Hepatitis C virus) and an alternative approach
The company plans to start patient screening shortly and the initial clinical supplies could be produced for qualifying patients in Canada and Europe in the third quarter of
In return, Alder has secured an equity stake in Vitaeris, which is engaged in the development of clazakizumab and other treatments for chronic inflammatory diseases. Alder will also
The company’s lead compound ALLN-177, an oral formulation of oxalate decarboxylase, is being developed to treat patients with disorders of oxalate metabolism. Allena Pharmaceuticals COO Louis Brenner said:
The deal expands AMRI’s API development and manufacturing operations as well as its presence in the European community. Euticals manufactures APIs primarily in Italy, Germany, France and the
The study, dubbed Resorce, enrolled 573 subjects who were randomized 2:1 to receive either regorafenib plus best supportive care (BSC) or placebo plus BSC. Patients were treated with
Based at BioCity, Nottingham, UK, Haemostatix is developing a pipeline of topical products for surgical bleeding. The company has developed a platform that utilizes synthetic peptide-based haemostats to
The company’s biologics license application included results from a pivotal phase 2 open-label, randomized trial that assessed the addition of olaratumab to doxorubicin chemotherapy in patients with advanced
The study, termed EMPIRE-CF (Evaluating Modulation of the Pulmonary Inflammatory Response in CF), will include approximately 30 sites across the EU, with sites in the United Kingdom, France,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.